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Abstract
Background: Hairy/Enhancer of Split (Hes) proteins are targets of the Notch signaling pathway and make up a class of basic
helix-loop-helix (bHLH) proteins that function to repress transcription. Data from Hes1 deficient mice suggested that Hes1,
like Notch1, is necessary for the progression of early T cell progenitors. Constitutive activation of Notch is known to cause T
cell leukemia or lymphoma but whether Hes1 has any oncogenic activity is not known.
Methodology/Principal Findings: We generated mice carrying a Hes1 transgene under control of the proximal promote of
the lck gene. Hes1 expression led to a reduction in numbers of total thymocytes, concomitant with the increased
percentage and number of immature CD8
+ (ISP) T cells and sustained CD25 expression in CD4
+CD8
+ double positive (DP)
thymocytes. Hes1 transgenic mice develop thymic lymphomas at about 20 weeks of age with a low penetrance. However,
expression of Hes1 significantly shortens the latency of T cell lymphoma developed in Id1 transgenic mice, where the
function of bHLH E proteins is inhibited. Interestingly, Hes1 increased expression of a subset of Notch target genes in pre-
malignant ISP and DP thymocytes, which include Notch1, Notch3 and c-myc, thus suggesting a possible mechanism for
lymphomagenesis.
Conclusions/Significance: We have demonstrated for the first time that Hes1 potentiates T cell lymphomagenesis, by up-
regulating a subset of Notch target genes and by causing an accumulation of ISP thymocytes particularly vulnerable to
oncogenic transformation.
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Introduction
T cell development requires the productive assembly and
expression of antigen receptor genes. For ab T cells, expression of
a functional T cell receptor b (TCR b) chain in complex with pre
Ta protein on CD4
2CD8
2 (DN) thymocytes promotes cellular
expansion and differentiation to the corresponding CD4+CD8+
(DP) stage through a CD8 immature single positive (ISP) stage
[1,2]. Next, functional rearrangement and expression of TCRa
chains lead to formation of surface ab TCR, which allows for
signals that induce further development to mature CD4 or CD8
single positive (SP) T cells [3]. To ensure the development of T
cells able to recognize MHC/peptide complexes, thymocytes are
programmed to undergo apoptosis if they do not receive pre-TCR
or TCR-mediated survival signals. Precise regulation of the signals
that control proliferation vs. apoptosis is therefore critical for
ensuring the proper differentiation of thymocytes that may be
particularly vulnerable to oncogenic transformation during this
highly dynamic phase of T cell development.
Notch signaling pathways regulate lineage specification decisions
during development of numerous tissues [4]. Activation of
transmembrane Notch receptors is triggered by interaction with
Notch ligands Jagged and Delta-like on adjacent cells that results in
proteolytic cleavage of Notch and subsequent release of the
intracellular domain (IC) [5]. Notch-IC is then transported into
the nucleus and associates with RBP-Jk/CBF-1, resulting in the
activation of target genes including the Hes family of proteins [6–8].
Notch mediates the development of T cells from multipotent
lymphoid progenitors derived from bone marrow (BM) precursors
that enter the thymus via the bloodstream [9–13]. Moreover,
expression of a constitutively active form of Notch1 in BM
progenitors results in ectopic T cell development outside the
thymus and T cell leukemia [14,15]. Hes1 is a basic Helix-Loop-
Helix (bHLH) protein and forms homodimers to repress transcrip-
tion by binding to N boxes and recruiting the transcriptional co-
repressor Groucho [16,17]. Data from analyses of Hes1 deficient
micesuggested that Hes1isrequiredfornormalT celldevelopment,
particularlyin the expansion of early T cell progenitors [18]. On the
other hand, overexpression of Hes1 in BM-derived progenitors
impairs both myeloid and B lymphocyte differentiation [19].
T cell acute lymphoblastic leukemia (T-ALL) in humans is
frequently associated with mutations or chromosomal rearrange-
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of activated forms of Notch induces rapid T cell transformation
[15]. In childhood T-ALL, Tal1/SCL is often found to be
expressed and thought to inhibit the function of bHLH proteins
such as E2A and HEB, collectively called E proteins [22,23].
Interestingly, a large fraction of these T-ALL cases accumulate
activating mutations in the Notch1 gene [24]. Likewise, gain of
function mutations within Notch are also found in several animal
models of T-ALL such as T cell lymphoma developed in E2A
deficient mice [25,26]. Thus, Notch appears to cooperate with loss
of E protein function in T cell tumorigenesis. The precise
mechanism by which Notch activation leads to transformation is
still unclear, though several potential targets have been identified
[7,27,28]. To determine whether constitutive expression of Hes1
might contribute to T cell transformation, we have generated
transgenic mice that express Hes1 from the proximal Lck
promoter. We find that constitutive expression of Hes1 in the
thymus leads to T cell lymphomas with low efficiency. However,
Hes1 promotes rapid tumorigenesis in a well-studied model of T-
ALL in which expression of Id1 inhibits the function of E2A and
HEB transcription factors [29], whose deficiency leads to T cell
lymphoma [30]. Therefore, we demonstrate for the first time that
Hes1 itself possesses oncogenic activity. We also show that ectopic
expression of Hes1 in pre-malignant ISP and DP thymocytes
increases a subset of genes known to be activated by Notch
signaling, such as Notch1, Notch3, and c-myc, thereby providing a
potential mechanism by which Hes1 potentiates tumorigenesis.
Materials and Methods
Mouse models
To generate Hes1 transgenic mice, sequence encoding an HPC4
epitope tag was attached onto the 59-end of murine Hes1 cDNA to
facilitate detection of transgenic protein [31]. The construct was
then cloned into the vector containing the proximal promoter of the
lck gene [32]. The DNA fragment containing the transgene was
injected into FVB/N blastocysts and two lines (H5 and H12) were
selectedfor continuedbreedingand analysis. Id1transgenicmice, in
which the Id1 gene is expressed from the same lck promoter, were
previously described as Id1-28 by Kim et al. [29].
Flow Cytometry and cell sorting
Single cell suspensions from lymphoid tissues were stained with
fluorochrome-conjugated antibodies and analyzed on a BD LSRII
flow cytometer using standard procedures. To delineate DN
thymocyte populations, thymocyte suspensions were stained with
lineage specific antibodies for CD8, TCRc/d, B220, Gr1 and
CD3. Upon gating on lineage negative cells, DN populations were
further assayed based on CD44 and CD25 staining. The CD8
immature single positive (ISP) and DP cell populations were
isolated based on CD4, CD8 and TCRb expression after gating
out all cells staining with propidium iodide. The ISP population
was defined as CD4
-CD8
+TCRb
lo cells. Cell sorting was
performed on a MoFlo (Dako Colorado, Inc., Fort Collins, CO)
using thymocytes from mice of different genotypes around 3 weeks
of age.
Real time PCR analysis
Total RNA from sorted T cells was isolated using Trizol reagent
as per manufacturer’s protocol. Five mg of total RNA was then used
to synthesize cDNA using M-MLV reverse transcriptase (Invitrogen,
Carlsbad, CA). Quantitative PCR was performed using SYBRgreen
1 (Qiagen, Valencia,CA) on an Applied Biosystems 7500 Real Time
PCR and software analysis system. The primers used to detect
Notch1, Notch3, Deltex1 and c-myc were purchased from Qiagen.
Other primers are total Hes1F, CCAGCCAGTGTCAACACGA;
total Hes1R, AATGCCGGGAGCTATCTTTCT; endogenous
Hes1F, TCCTTGGTCCTGGAATAGTGCTA; endogenous
Hes1R, ACTGAGCAGTTGAAGGTTTATTATGTCT; Nrarp
F, CTACACATCGCCGCTTTCG; and Nrarp R, CGCGTAC-
TTGGCCTTGGT.
Sequence analysis of the Notch1 allele
Genomic DNA was isolated from cells of individual tumors, of
which tumor cells constitute at least 90%, and used for PCR-
mediated amplification of the PEST domain of the Notch1 gene
with the following primers: TACCAGGGCCTGCCCAACAC
and GCCTCTGGAATGTGGGTGAT. The resulting PCR
products were separately cloned into the pGEM-T easy vector
(Promega, Madison, WI). At least 5 colonies were analyzed by
DNA sequencing to identify mutations.
Statistical analyses
Student’s t tests were performed using the Prism 5 software.
Kaplan-Meier curves were constructed and the age of median
survival was determined using the same software. Statistical
significance was estimated with the log-rank test.
Results
Generation and characterization of Hes1 transgenic mice
We have generated transgenic mice in which Hes1 cDNA is
expressed from the proximal promoter of the lck gene, which
directs gene expression beginning at the DN stages of T cell
development. Two independent lines, H5 and H12, were
characterized and used in this study. Using quantitative PCR
assays, we found that the H5 and H12 lines contained about 15
and 55 copies of the transgene, respectively (Fig. 1A). Corre-
spondingly, we detected slightly higher levels of Hes1 protein level
in the H12 line compared to the H5 line using antibodies against
Hes1 or the HPC4 tag (Fig. 1B). The level of Hes1 in wild type
thymocytes was undetectable with the anti-Hes1 antibodies
commercially available. We next compared levels of total Hes1
transcripts in subsets of thymocytes (Fig. 1C). Although endoge-
nous Hes1 was expressed at high levels in wild type DN
thymocytes, its levels in ISP and DP cells were extremely low. In
comparison, transgenic expression elevated total Hes1 levels by 6–
32 folds in the DN compartments. However, the levels of Hes1 in
ISP and DP thymocytes of the transgenic mice were 3,214 and
22,901 times higher than their wild type counterparts. These
profound differences in Hes1 levels could have significant impact
on the transgenic thymocytes.
Since Hes1 is a bHLH protein and suggested to serve as an
inhibitor of E proteins [33,34], we tested its ability to influence the
DNA binding activities of E proteins using electrophoretic mobility
shift assays and an E-box probe. Nuclear extracts were isolated
from CD4
2CD8
2 DN thymocytes of 3 week-old wild type, Hes1
or Id1 transgenic mice (Fig. 1D). While the DNA binding activity
in extracts isolated from Id1-expressing cells was almost com-
pletely abolished, the level of E-box binding complexes in Hes1
transgenic thymocytes was comparable to that detected in wild
type cells. We also did not detect any new DNA binding
complexes that might correspond to E protein and Hes1
heterodimers. Since the DNA binding activity was not reduced,
E protein levels were unlikely diminished. Collectively, it appears
that Hes1 did not significantly alter the function of E proteins in
these transgenic mice.
Hes1 Induces T Cell Lymphoma
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To investigate the effect of constitutive expression of Hes1 on
thymocyte development, we analyzed thymocytes from 3 to 5-
week old mice by flow cytometry and found an approximate 4-
fold reduction in total thymocyte counts in Hes1 transgenic mice
compared to littermate controls (Fig. 2A). This was accompanied
by a decrease in the ratio of CD4 to CD8 SP thymocytes, (Fig. 2A
and B). Although wild type CD4
+CD8
+ thymocytes no longer
express CD25, the majority of Hes1 transgenic DP thymocytes
express substantial levels of CD25 on their surface (Fig. 2C). The
reduction in thymic cellularity was also accompanied by an
increase in the percentage of CD4
2CD8
2 double negative cells
(Fig. 2A and B). Furthermore, staining DN cells with antibodies
against CD44 and CD25 revealed a consistently larger propor-
tion of DN3 cells expressing intermediate levels of CD25 (20%
versus 12%) in Hes1 transgenic mice (Fig. 2D). These cells could
represent those transitioning from the CD44
2CD25
+ DN3 stage
to the CD44
2CD25
2 DN4 stage following productive TCRb
rearrangement and functional pre-Ta expression. The percent-
ages of DN4 cells were variable in individual Hes1 transgenic
mice and were not significantly different from those of wild type
mice.
One of the striking phenotypes of Hes1 transgenic mice was the
accumulation of cells at the CD8 immature single positive (ISP)
stage, which is an intermediate stage that occurs during the
developmental transition from DN to DP stages [35,36]. The ISP
stage is characterized by low levels of TCRb expression in
comparison with that found on mature CD8
+ thymocytes. We
found a significant increase in the proportion of CD8
+ thymocytes
that expressed low levels of TCRb in Hes1 transgenic mice
compared to wild type littermates (Fig. 3A). Compared to wild type
mice, the average percentages of the phenotypic ISP cells were
increased by approximately 7 fold whereas the total numbers of
these cells were 3 times higher in Hes1 transgenic mice (Fig. 3A). To
rule out the possibility that these phenotypic ISP cells represent
CD8
+ cells without the rearrangement or expression of the TCRb
gene, we performed intracellular staining with antibodies against
TCRb. As shown in Fig. 3B, the peak level of intracellular TCRb in
CD8
+ cells of Hes1 transgenic mice fell between those of DP and
CD4
+ cells. In contrast, the level in CD8
+ cells of wild typemicewas
similar to those of CD4
+ cells. This is consistent with the notion that
a significant fraction of CD8
+ cells expressed lower levels of TCRb.
Figure 1. Generation and analysis of Hes1 transgenic mice. (A)
Copy numbers of the Hes1 transgene determined using real-time PCR
with primers as depicted by the arrows in the diagram of the transgenic
construct. HPC4-tag was added to the N-terminus of Hes1. Numbers of
Hes1 coding sequences in the H5 and H12 lines of Hes1 transgenic mice
are shown as relatives to that of WT mice. (B) Hes1 protein expressed by
total thymocytes from WT and the H5 and H12 lines of Hes1 transgenic
mice were detected with antibodies against Hes1 or the HPC4 tag.
Levels of tubulin were used as loading controls. (C) Comparison of total
Hes1 mRNA levels encoded by the endogenous gene and transgene in
thymocyte subsets sorted from WT and Hes1 (H12) transgenic mice. The
level of Hes1 in each sample was normalized against that of b-actin.
Expression levels relative to that in WT DP cells are shown in log scale.
The fold of increase in Hes1 transgenic cells relative to their wild type
counterparts is labeled on top of the bars. Data shown in (A) and (C) are
means6SD of triplicates. (D) Electrophoretic mobility shift assay for E-
box DNA-binding activity. Nuclear extracts were prepared from sorted
DN thymocytes from the indicated mouse strains at the age of 3–4
weeks, and incubated at room temperature with
32P–labled probes and
1 mg of poly(dI:dC) as described [51]. For supershift assays, 1 ml of anti-
E47 antibodies was added at the end of binding reaction and incubated
for 5 minutes. DNA binding and super-shifted complexes are indicated
by closed and open arrows. Oct-1 binding was used as a control.
doi:10.1371/journal.pone.0006678.g001
Hes1 Induces T Cell Lymphoma
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+ cells failed to express TCRb, its
staining intensity would have been similar to that of the major peak
seen in DN3 cells (Fig. 3B). Therefore, we concluded that Hes1
transgenic mice have an accumulation of ISP cells.
Consistent with this finding, BrdU incorporation assay detected
an increase in the percentage of BrdU positive cells in total
thymocytes of Hes1 transgenic mice (Fig. 3C). Co-staining for
CD4, CD8 and TCRb with anti-BrdU showed that the proportion
of BrdU positive cells in the total CD8
+ population was
dramatically different between wild type and Hes1 transgenic
cells. However, when analyzed separately for mature CD8
+ and
ISP subsets, the percentages of BrdU incorporating cells were
similar, suggesting that the larger fraction of BrdU positive cells in
the total CD8
+ population was due to the increased representation
of ISP. These results thus suggested that Hes1 expression did not
alter the rate of BrdU incorporation, which was also found to be
similar in other thymocyte subsets (data not shown).
Collectively, constitutive expression of Hes1 impairs develop-
ment of thymocytes at several stages. However, no significant
abnormalities were detected in peripheral T cells, particularly in
regulatory T cells, despite the elevated expression of CD25 in
thymocytes (Fig. 2).
Hes1 transgenic mice develop CD25
+ thymic lymphomas
Ectopic expression of Notch proteins leads to the rapid
development of thymic lymphomas in mice. Given that Notch
induces the expression of Hes1 during thymopoiesis, we
investigated whether Hes1 expression alone is sufficient for T cell
transformation. T cell lymphomas were found in greater than 25%
of either the H5 or H12 line of Hes1 transgenic mice with an
average age of onset of 20 weeks (Fig. 4 and Table 1). Cell surface
expression of T cell markers was found to vary between tumor
samples, though the majority expressed both CD4 and CD8. The
majority of lymphomas also expressed high levels of CD25,
consistent with previous studies of Notch3-induced T cell
lymphomas [37].
All mice that developed tumors had clear evidence of thymic
involvement, though tumor cells were frequently detected in
peripheral tissues including spleen and lymph nodes. Whenever
spleen or lymph node involvement was detected, the surface
marker phenotypes on leukemia cells were identical to that of cells
isolated from the thymus of the same animal, suggesting that
tumorigenesis originated in the thymus, which was followed by
metastasis to peripheral lymphoid organs.
Hes1 synergizes with Id1 in tumorigenesis
Models of T cell leukemia or lymphoma involving activated
Notch display rapid onset leukemias that develop at about 6–8
weeks of age [14,37]. In contrast, overexpression of Hes1 caused T
cell lymphoma with a longer latency and lower penetrance (Fig. 4).
This suggested that activation of Hes1 transcription by Notch
signaling could not fully explain the potent oncogenic effects of
Notch receptors. We thus explored possible cooperation between
Hes1 and other factors in T cell lymphomagenesis. Tumorigenesis
due to loss of E protein function is another well studied example of
T-ALL [29,30,38,39]. Previous studies have also shown that
expression of Id1, a naturally occurring inhibitor of E proteins,
leads to a high incidence of thymic lymphomas in mice [29].
Constitutive expression of Id1 from the lck proximal promoter
leads to tumorigenesis with the age of 50% tumor free survival
being 20 weeks (Fig. 4). When Hes1 transgenic mice were crossed
with these mice, the resulting trans-heterozygotes expressing both
Hes1 and Id1 developed thymic lymphomas at 100% frequency
within 25 weeks and with a median onset of only 14 weeks (Fig. 4).
The enhancement of tumorigenesis by Hes1 was statistically highly
significant. Thus it appears that Hes1 and Id1 act synergistically to
promote tumorigenesis.
Figure 2. Analysis of thymocyte development in Hes1 trans-
genic mice. (A) Cell numbers of the different thymocyte populations
are shown as an average of 4 mice at 3–5 weeks of age. (B) FACS
analysis was performed on thymocytes isolated from individual wild
type (WT) or Hes1 transgenic littermates and stained with indicated
antibodies. (C) CD4
+CD8
+ DP cells shown in (B) were further analyzed
for CD25 expression. (D) Thymocytes isolated from WT or Hes1
transgenic littermates were stained with antibodies against CD8,
B220, TCRc/d, GR1 and CD3. The lineage negative thymocytes were
further stained with anti-CD44 and anti-CD25. Percentages of cells in
each gate are as labeled.
doi:10.1371/journal.pone.0006678.g002
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To understand the mechanism whereby Hes1 promotes T cell
lymphomagenesis, we tested whether overexpression of Hes1 might
have similar effects as Notch signaling. We generated cDNA from
RNA isolated from various thymocyte populations of 3 week-old
wild type and Hes1 transgenic mice, which did not exhibit any sign
of thymic lymphoma. We next performed quantitative RT-PCR
assays of several Notch regulated genes. As shown in Fig. 5A and B,
mRNA levels of both Notch1 and Notch3 in wild type thymocytes
progressively increased in the DN compartments but dramatically
decreased in ISP and DP subsets. However, expression of the Hes1
Figure 3. Accumulation of ISP in Hes1 transgenic mice. (A) FACS
analysis was performed on thymocytes isolated from individual 3 to 5
weeks old WT or Hes1 transgenic littermates with antibodies against
CD4, CD8 and TCRb. The percentage of TCRb
low/2 cells in total CD8
single positive cells is shown in the histograms. Data shown are
representatives of independent analyses of 7 WT and 11 Hes1
transgenic mice. Percentages of ISP in total CD8
+ thymoyctes as well
as absolute numbers of ISP thymocytes are shown in bar graphs as
means6SE. (B) Thymocytes isolated from individual WT or Hes1
transgenic mice were stained for surface markers with antibodies
against CD4, CD8, CD44, and CD25, which was followed by intracellular
staining for TCRb. The fluorescent intensities of color-coded popula-
tions in WT or Hes1 transgenic mice are overlaid in histogram.
Representatives of independent analyses of multiple mice are shown.
(C) Thymocytes isolated from individual WT or Hes1 transgenic
littermates 1.5 hours after intraperitoneal injection with 1 mg BrdU.
After staining with antibodies against CD4, CD8, CD44, and CD25,
intracellular staining was performed using a labeling kit from BD
Biosciences (San Jose, CA). Percentage of cells in each gate is indicated.
Representatives of independent analyses of multiple mice are shown on
the top. The percentage of BrdU labeling cells within indicated
populations are shown on the bottom as means6SD.
doi:10.1371/journal.pone.0006678.g003
Figure 4. Incidence of thymic lymphomas in Hes1 and Id1
transgenic mice. Different strains of mice as indicated by symbols
shown were monitored for onset of thymic lymphoma using outward
signs such as respiratory distress. The presence of tumors was
confirmed by autopsy. The cohort of Id1/Hes1 double transgenic mice
included approximately equal representations of progenies of Id1
transgenic mice crossed with either the H5 or H12 line of Hes1
transgenic mice. Median time span of tumor free survival was calculated
using the Prism software and shown below the graph. Statistical
significance between the 50% tumor free survival in Id1 single and Id1/
Hes1 double transgenic mice was determined using the Log-rank test.
Numbers of animals in each cohort (n) are listed in the inset.
doi:10.1371/journal.pone.0006678.g004
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Notch3 levels in ISP and DP cells of Hes1 transgenic mice were
similar to the peak level of Notch3 found in wild type DN3
thymocytes. Hes1 expression had little or no influence on the
already high levels of Notch1 and Notch3 in DN subsets.
Next, we examined the effect of Hes1 on expression of the c-
myc gene, which is known to be a downstream target of Notch
signaling [7,8]. Like the expression patterns of Notch genes, c-myc
levels were high in DN subsets of wild type mice and gradually
decrease as the cells enter the ISP and DP stages (Fig. 5C). Hes1
again sustained c-myc expression in ISP cells at a level comparable
to that seen in wild type DN3 cells. In DP thymocytes of Hes1
transgenic mice, the level of c-myc was 11 fold higher than their
wild type counterparts. High levels of c-myc expression were also
observed in ISP cells of Id1
tg/Hes1
tg but not in Id1
tg mice (data
not shown). Given the potent oncogenic effect of c-myc, up-
regulation of c-myc by Hes1 could significantly contribute to the
lymphomagenic effect of Hes1.
To address whether Hes1 expression uniformly enhances the
transcription of all Notch targets, we interrogated additional target
genes. Nrarp is considered a gene regulated by Notch and serves as
a negative regulator of Notch signaling [40]. However, its
expression pattern in wild type thymocytes did not follow the
same trend as other Notch targets (Fig. 5D). Nevertheless, Hes1
increased Nrarp levels by less than 2.9 fold in various subsets.
Surprisingly, two of the best known target genes of Notch
signaling, Deltex1 and endogenous Hes1, were not stimulated by
Hes1. Instead, transgenic expression of Hes1 resulted in reduction
in most of the subsets. In particular, Deltex1 and endogenous Hes1
levels in the ISP faction were reduced by 5 and 7 fold, respectively.
Therefore, it appears that ectopic expression of Hes1 selectively
up-regulates a subset of but not all Notch target genes in pre-
malignant thymocytes. Whether this is achieved by facilitating
Notch-mediated transcription or through the action of indepen-
dent mechanisms remains to be determined.
Acquisition of stabilizing mutations of the Notch1 gene
in Id1 and Hes1 expressing tumors
Gain-of-function mutations in the Notch1 gene are frequently
found in several models of T cell lymphoma as well as in human T
cell leukemias, including those resulted from loss of E protein
function [24–26]. We were therefore interested in learning if
expression of one of the Notch targets, Hes1, could by-pass the
need for mutations of Notch receptors. We surveyed 7–10
individual tumors developed in Id1 and Hes1 single or double
transgenic mice for mutations in the PEST domain capable of de-
stabilizing Notch1. PEST domain mutations represent the
majority of mutations found in mouse T cell lymphomas and
are thus good representatives. As shown in Fig. 6A, most of the
alterations led to frame-shift or nonsense mutations in the gene,
which is likely to abolish the function of the domain and cause
stabilization of the mutant proteins. It is worth noting that there
appear certain hotspots in PEST domain prone to mutations and
most of the mutations occur at the N-terminus of the domain
(Fig. 6A). Unexpectedly, similar percentages of tumors from Id1
and Hes1 transgenic mice (60% and 66%, respectively) accumu-
lated mutations in the Notch1 gene (Fig. 6B). Three out of seven
(43%) double transgenic tumors also contained mutations and this
percentage, given the limited number of cases, is statistically
insignificant compared to the 60–66% occurring in single
transgenic tumors. Taken together, it appears that although
Hes1 is able to turn on a subset of Notch targets, further
enhancement of Notch signaling could provide advantages for
tumor growth or survival. However, these PEST domain mutants
alone are not sufficient to cause T cell leukemia [41].
Analyses of gene expression in Hes1 transgenic tumors
To obtain further insights into the mechanism underlying tumor
initiation or growth, we examined mRNA levels of Notch targets in
thelymphomas.We sampled 4 Hes1transgenictumorsalong with 3
Id1 transgenic tumors as controls. Hes1 tumor A had a 140-bp
insertion in the PEST domain that resulted in a frame-shift whereas
theother threetumorsdidnothavemutationsinthisregion.Tumor
A of Id1 transgenic mice did not carry a PEST domain mutation
and Notch1 sequence in the other two tumors were not analyzed.
All tumors from Hes1 transgenic mice produced high levels of Hes1
butId1
tgtumorsAandB hadverylowlevelsandtumorCexpressed
a moderate level of Hes1 (Fig. 7A). Consistent with uniformly high
levels of Hes1, all Hes1
tg tumors expressed higher levels of c-myc
(Fig. 7B). This agrees with our finding of elevated c-myc levels in
pre-malignant ISP and DP thymocytes (Fig. 5). Although transgenic
expression of Hes1 did not increase Deltex1 expression in pre-
malignant thymocytes, elevated Deltex1 expression was seen in all
Hes1
tg tumors and Id1
tg tumor C (Fig. 7D). Expression of Notch1
and Notch3 was elevated in Hes1
tg tumors A, C and D, as well as
Id1
tg tumor C (Fig. 7E and F). Intriguingly, Hes1
tg tumor B had
very lowlevels of Notch1andNotch3, aswell aslowerlevelsofHes1
and Deltex1 than other tumors. However, this tumor produced the
highest levels of c-myc and Nrarp (Fig. 7B and C). Likewise, Id1
transgenic tumor B expressed a large amount of c-myc without up-
regulating other Notch target genes except Nrarp. Collectively,
elevation of different subsets of Notch target genes appears to occur
in these T cell lymphomas of Hes1 transgenic mice. This probably
represents the end result of natural selection for expression of a
faction but not necessarily all of Notch targets, which in turn
facilitatetumorcellgrowthand survival.Nocorrelationbetweenthe
expression patterns of these genes and the surface phenotypes of the
tumors were detected in these analyses of limited numbers of
samples.
Discussion
Aberrant Notch signaling is well known to cause T cell leukemia
or lymphoma with high efficiency. Hes1 is one of the first known
Table 1. Hes1 expression induces thymic lymphoma in mice.
Tumor #
Age at onset
(weeks) Tumor phenotype Tissue involved
430 5 CD4
+CD8
+CD25
+ Thy,Spl, LN
786 8 CD4
+CD8
+CD25
+ Thy,Spl, LN
996 10 ND Thy,Spl, LN
382 10.5 CD4
+CD8
+CD25
+ Thy,Spl, LN
279 15 CD4
2CD8
+CD25
2 Thy
662 15 CD4
+CD8
+CD25
+ Thy
280 17 CD4
+CD8
+CD25
+ Thy
798 22 CD4
+CD8
+CD25
+ Thy
457 23 CD4
2CD8
+CD25
2 Thy
254 24 CD4
+CD8
+CD25
+ Thy
697 26 CD4
+CD8
+CD25
+ Thy
741 31 CD4
2CD8
+CD25
2 Thy,Spl, LN
633 47 ND Thy
doi:10.1371/journal.pone.0006678.t001
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[6]. Here, we show that ectopic expression of Hes1 predisposes
mice to develop T cell lymphoma, which suggests that Hes1 up-
regulation by Notch signaling is one of the components involved in
Notch-mediated tumorigenesis. However, Hes1 transgenic mice
develop lymphomas with a much longer latency and with a lower
frequency compared to Notch1 or Notch3 expressing animals
[37,42]. This indicates that additional mechanisms besides Hes1
up-regulation play a role in Notch-induced tumorigenesis.
We have also demonstrated that Hes1 expression acts
synergistically with Id1 to promote lymphoma development. Id1
is a naturally occurring inhibitor of bHLH E protein transcription
factors such as E2A. E proteins are considered tumor suppressors
because genetic ablation of the E2A gene results in T cell
Figure 5. Ectopic expression of Hes1 elevates mRNA levels of a subset of Notch target genes. Real-time RT-PCR assays were performed
using total RNA isolated from thymocyte subsets of WT and Hes1 (H12) transgenic mice as described for Fig. 1C. Relative levels of expression of each
indicated transcript are presented in reference to that in WT DP cells. N.D. stands for not detectable. Data are means6SD of triplicates. The ratio of
mRNA level in Hes1 transgenic versus WT cells is labeled on the top of the bar. Statistical significance was assessed with Student’s t-test. *, P,0.05, **,
P,0.01, ***, P,0.001.
doi:10.1371/journal.pone.0006678.g005
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genesis [29]. In addition, aberrant activation of Tal1, another
bHLH inhibitor of E proteins, is the most common cause of
human pediatric T cell acute lymphoblastic leukemia (T-ALL)
[22,43]. Transgenic expression of the p22 form of Tal1 also causes
T cell lymphoma in mice [44]. When both Hes1 and Id1 are
expressed in thymocytes, lymphomas develop rapidly in all
animals examined (Fig. 4). The age of 50% tumor-free survival
is 14 weeks. This efficiency is comparable to that seen in animals
expressing Notch-IC [42]. Does this mean that T cell lymphoma
resulting from constitutive Notch signaling involves both up-
regulation of Hes1 and down-regulation of E protein function?
This possibility is not entirely unreasonable because work from our
laboratory has shown that Notch signaling accelerates ubiquitin-
mediated degradation of E2A proteins in cellular environments
with sufficient Erk activities [45,46]. One can envision such a
scenario in T cells immediately following pre-T cell receptor (pre-
TCR) or TCR signaling. Notch signaling has also been shown to
stimulate expression of Id genes such as Id1 or Id3 [47,48].
Previous studies have revealed that loss of E protein function
lowers the thresholds of TCR signaling [49–51]. Furthermore,
Notch is known to facilitate T cell survival, which may contribute
significantly to the manifestation of T cell lymphoma.
It has been shown that tumors developed from E2A deficient or
Tal1 expressing T cells accumulate stabilizing mutations in the
Notch1 gene [24,25]. We found similar mutations in tumors
Figure 6. Mutations in the Notch1 gene from tumors developed in Id1 and Hes1 single or double transgenic mice. DNA samples
isolated from individual tumors from indicated transgenic strains were used as templates to amplify the sequence encoding the PEST domain of
Notch1. PCR products were cloned and sequenced as described in Materials and Methods. (A) Sequence of the mutations. Wild type Notch1
sequence in the relevant regions is shown in blue and amino acid numbers for each region are indicated. Mutant sequences from the tumors are
aligned underneath and the type of the mutation is indicated at the end of each sequence (FS=frame-shift, Stop=nonsense mutation). (B)
Frequency of Notch1 mutation. Numbers of tumors containing mutations and those with wild type sequence are depicted with black and blue bars,
respectively.
doi:10.1371/journal.pone.0006678.g006
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PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6678Figure 7. Analyses of gene expression in Hes1 transgenic T cell lymphomas. Total RNA was isolated from individual lymphoma samples of
Hes1 or Id1 transgenic mice. Expression levels of indicated genes were determined in three independent experiments as described for Fig. 5 and
compared to that in WT thymocytes.
doi:10.1371/journal.pone.0006678.g007
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expression cannot entirely substitute for enhanced Notch signaling
during tumor progression. However, it is important to point out
that ectopic expression of Hes1 did increase the frequency and
shorten the latency of lymphomagenesis in Id1 transgenic mice.
Hes1-mediated expression of a subset of Notch target genes
occurred in pre-malignant thymocytes, which could constitute
partial Notch signaling and lead to weak intrinsic oncogenic
effects. Furthermore, Hes1 acts synergistically with Id1 to
significantly enhance tumorigenesis in double transgenic mice.
Although mutations in the Notch1 gene have been detected in
various T cell leukemias or lymphomas triggered by loss of
function of transcription factors or increases in signaling
transduction [24,25,41], the exact role of these mutants is not
well understood. For instance, the PEST domain mutants have
very low activities in Notch-mediated transcription and T cell
differentiation. They also fail to cause T cell leukemia when
expressed from retroviral vectors [41]. In contrast, activation of a
subset of Notch target genes occurs in pre-malignant thymocytes
of Hes1 transgenic mice, which do not carry mutations in the
PEST domain (data not shown). Therefore, the contribution of
other oncogenic factors should not be dismissed simply because
stabilizing Notch mutations are found in the tumors. These Notch
mutants could merely cooperate with other oncogenic factors to
promote the growth of existing tumor cells.
How does Hes1 potentiate tumor formation by itself and in
cooperation with E protein inhibitors? Examination of T cell
development in Hes1 transgenic mice revealed an accumulation of
CD8 immature single positive cells. This stage coincides with the
proliferative burst following pre-TCR expression, making cells
uniquely susceptible to tumorigenesis. This is particularly relevant
to the situations when E protein functions are compromised. For
example, heterozygous Id1 transgenic mice, where T cell
development is partially impaired, develop high incidence of T
cell lymphoma [29]. However, homozygous Id1 transgenic mice,
in which T cell development is blocked at the DN1 stage, do not
develop T cell lymphoma (data not shown). On the other hand,
conditional disruption of the E2A gene in DP thymocytes also did
not result in thymic tumors [52], suggesting the window of
opportunity for transformation occurs prior to this stage. It is also
interesting that retrovirus-mediated expression of Hes1 in bone
marrow cells does not promote tumorigenesis in transplant
recipients [18,19]. This may be explained by the differences in
target cells and the timing of Hes1 expression.
At the molecular level, we have detected elevated levels of c-myc
expression in pre-malignant thymocytes, particularly in the ISP
and DP populations, where c-myc is normally expressed at low
levels. It is well documented that c-myc exhibits potent
transforming activity in T cell leukemia and lymphoma [53,54].
The c-myc gene is a known target of the Notch signaling pathway
[7], and with Hes1 being downstream from Notch receptor
signaling, it is therefore plausible that Hes1 can cause c-myc up-
regulation. Interestingly, c-myc, along with Notch1, Notch3 and
CD25, is among a subset of Notch target genes to be stimulated by
Hes1. In contrast, Deltex1 and endogenous Hes1 genes were not
up-regulated in pre-malignant thymocytes by transgenic Hes1.
Likewise, PTEN expression was not altered in pre-malignant
thymocytes of Hes1 transgenic mice (data not shown). These
findings argue against the idea of a uniform elevation of Notch
signaling in pre-malignant Hes1 transgenic thymuses. Instead,
they suggest that different Notch target genes are regulated
differently, or at least, have different thresholds for Notch signals.
This notion is further reaffirmed by data obtained from a limited
analysis of gene expression in Hes1 transgenic tumor samples,
showing expression of a combination of different Notch targets at
varying levels in different tumors.
Despite the positive effects of Hes1 on gene expression, Hes1 is
known to repress transcription by binding to N-box DNA
sequences and recruiting the transcriptional co-repressor, Groucho
[16,17]. How Hes1 conversely brings about increases in gene
expression needs to be understood in the future. Up-regulation of
Notch targets by Hes1 constitutes a positive feedback for Notch
signaling. Elucidation of the molecular mechanisms by which
Notch signaling and its downstream effectors influence tumori-
genesis will facilitate therapeutic intervention of T cell leukemia
and lymphoma and also shed light on the oncogenic effect of
Notch on other cell types.
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